HeraMED Limited

HMD

AU0000028367

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 12:50:07 2024-04-02 am EDT			5-day change	1st Jan Change
0.0175 ^AUD	-12.50%		0.00%	-27.08%

Mar. 13	HeraMED Partners With FemBridge for Maternity Health Service; Shares Jump 15%	MT
Mar. 11	Heramed Limited Announces Board Changes	CI

HeraMED Limited Appoints David Hinton as Director

December 10, 2018 at 09:10 pm EST

HeraMED Limited appointed David Hinton as Director. The date of appointment is August 21, 2018.

Latest news about HeraMED Limited

HeraMED Partners With FemBridge for Maternity Health Service; Shares Jump 15%	Mar. 13	MT
Heramed Limited Announces Board Changes	Mar. 11	CI
HeraMED Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
HeraMED Enters Strategic Collaboration with PHI Research	Jan. 21	MT
HeraMED Limited Announces Emily Slade to Resign as Non-Executive Director	Jan. 16	CI
HeraMED Enters Strategic Collaboration with GPEx	Jan. 15	MT
HeraMED Signs Deal with US-based Wingwomen for Cardio Initiative in Pregnant Women	Dec. 19	MT
HeraMED Concludes First Tranche of AU$1.25 Million Share Placement	Dec. 15	MT
HeraMED Signs Partnership Agreement with Telstra Health; Shares Climb 4%	Nov. 20	MT
HeraMED Launches Clinical Trial for Maternity Care Platform; Shares Surge 36%	Nov. 07	MT
HeraMED CEO Steps Down; CFO Transitions to EVP Role; Shares Surge 33%	Nov. 07	MT
HeraMED Limited Limited Announces Resignation of David Groberman as Chief Executive Officer with Immediate Effect	Nov. 07	CI
HeraMED Limited Announces Resignation of David Groberman as Managing Director	Nov. 07	CI
HeraMED Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-18	CI
Jianmin Pharmaceutical Group Co.,Ltd. completed the acquisition of 6.13% stake in HeraMED Limited from Hua Li Pharmaceutical Group Co.,Ltd.	23-07-24	CI
HeraMED Completes AU$2.58 Million Placement	23-07-13	MT
HeraMED Transitions Chair to Executive Role	23-07-03	MT
HeraMED's US Partner Signs Three-Year Commercial Deal with Caduceus Medical Group	23-06-15	MT
HeraMED Signs Enterprise Agreement with Fond for HeraCARE Platform; Shares Decline 4%	23-05-31	MT
Australian Shares Inch Down as Market Weighs Cooling, But Still High, US Inflation	23-05-11	MT
Heramed Signs Deal with Perth-based Private OB-GYN Group for HeraCARE Deployment; Shares Climb 10%	23-05-10	MT
Heramed Limited Announces Board Changes	23-04-19	CI
Transcript : HeraMED Limited - Special Call	23-03-21
HeraMED Limited Auditor Raises 'Going Concern' Doubt	23-03-21	CI
HeraMED Signs Deal with Queensland Public Healthcare Provider to Test Maternity Care Platform	23-03-21	MT

Hera Med Ltd is an Israel-based company that develops pregnancy monitoring solutions for home and professional use. It offers hardware solutions supported by software applications. Its product HeraBEAT, is a medical-grade, clinically-validated and connected Ultrasound Fetal Doppler device predominantly for use by an expectant mother to self-monitor her fetusâ heart rate (FHR) at home. HeraBEAT communicates with any smartphone (iOS/Android) through Bluetooth Low Energy (BLE). A mother can hold or strap the HeraBEAT device to her abdomen, and the collected data is transmitted to her smartphone where the relevant readings are displayed through an interface. The Company also develops a service model which includes a homecare pregnancy solution. In addition, the Company develops artificial intelligence (AI), machine-learning, computerized algorithms to monitor and analyze the data so a healthcare professional or home user is informed of the wellbeing of the fetus.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company